Prospective Evaluation of a Circulating Tumor Cell Sensitivity Profile to Predict Response to Cisplatin Chemotherapy in Metastatic Breast Cancer Patients

BACKGROUND: Cisplatin (cDDP) has regained interest for metastatic breast cancer (MBC) patients, given the platinum sensitivity in subtypes and better manageable toxicity. Here, the primary aim was to determine whether molecular characteristics of circulating tumor cells (CTCs) could identify patient...

Descripción completa

Detalles Bibliográficos
Autores principales: de Kruijff, I. E., Sieuwerts, A. M., Beije, N., Prager - van der Smissen, W. J. C., Angus, L., Beaufort, C. M., Van, M. N., Oomen - de Hoop, E., Jager, A., Hamberg, P., de Jongh, F. E., Kraan, J., Martens, J. W. M., Sleijfer, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8269318/
https://www.ncbi.nlm.nih.gov/pubmed/34249756
http://dx.doi.org/10.3389/fonc.2021.697572

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8269318/
https://www.ncbi.nlm.nih.gov/pubmed/34249756
http://dx.doi.org/10.3389/fonc.2021.697572

Ejemplares similares